Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171950 | 0.84 | EPHX1 (0.72) | EPHX1NAAAHPGDKMT2A | |
| SCHEMBL2199000 | 0.84 | EPHX1 (0.72) | EPHX1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15975484 | 0.83 | EPHX1 (0.71) | EPHX1NAAALMNAHPGDMEN1 | |
| SCHEMBL1690703 | 0.82 | EPHX1 (0.69) | EPHX1NAAA | |
| SCHEMBL13625190 | 0.79 | EPHX1 (0.65) | EPHX1ALDH1A1NAAAKMT2A | |
| SCHEMBL25236588 | 0.77 | EPHX1 (0.61) | EPHX1 | |
| Nitrobenzene SCHEMBL28019505 | 0.76 | EPHX1 (0.67) | EPHX1ALDH1A1MEN1KMT2A | |
| SCHEMBL25285565 | 0.76 | EPHX1 (0.60) | EPHX1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30802295 | 0.75 | SIGMAR1 (0.60) | EPHX1ALDH1A1MAPTLMNA | |
| SCHEMBL13625188 | 0.75 | EPHX1 (0.78) | EPHX1ALDH1A1NAAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885ALDH1A1 613/4885NAAA 294/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | EPHX1 1/4885ALDH1A1 741/4885NAAA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.